MEDIROM Healthcare Technologies Inc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Filing of Form 20-F for the Fiscal Year Ended December 31, 2025 | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Average Revenue Per Customer (Salon Operation Business) Quarterly7.8KTarget: Exceed Japanese industry average of approximately 4,806 JPY
Repeat Customer Ratio (Salon Operation Business) Quarterly78.0%Target: Maintain stable repeat ratio around 77-78%
Cumulative Users of Specified Health Guidance (Lav App) Quarterly13.2KTarget: Expand user base through partnerships with health insurance providers
Cumulative World ID Verifications (Orb Devices) Quarterly31KTarget: Scale verifications through nationwide deployment of Orb devices
Watch Items
- Nasdaq Listing Rule 5250(c)(1) Compliance (Delayed Form 20-F)Trigger: Failure to submit a compliance plan to Nasdaq by July 27, 2026, or failure to file the Form 20-F for the fiscal year ended December 31, 2025, by the final extended deadline (up to November 11, 2026)Action: Submit a comprehensive remediation plan to Nasdaq on or before July 27, 2026, and file the overdue Form 20-F to avoid delisting proceedings.
- Tools for Humanity Master Service Agreement ExecutionTrigger: Scaling Orb device installations toward the target of 3,000 nationwide locations in JapanAction: Monitor the deployment rate of Orb devices and track progress toward the projected $39 million in pre-tax income over two years.
- Liquidity and Working Capital DeficitTrigger: Short-term assets failing to cover short-term liabilities (working capital deficit) and high debt-to-equity ratioAction: Evaluate cash flow from operations, monitor debt service capabilities, and assess the need for additional capital raises or equity offerings.
Research as of 20 Jun 2026